CERTAIN DIHYDROPYRIDINE (DHP) derivatives, such as (Ϯ)-BAY K 8644 (BAYK) and (ϩ)-SDZ202-791, are used widely as specific agonists for the L-type Ca 2ϩ channel located in the surface membrane of many excitable cells, including the heart. Numerous studies (4, 16, 18, 22) demonstrate their ability to increase Ca 2ϩ current (I Ca ) magnitude, slow inactivation, and produce a positive inotropic action in cardiac tissues. Recent work (6, 12, 13, 17) also suggests that additional actions of BAYK may include an effect on the cardiac sarcoplasmic reticulum (SR) that could influence excitationcontraction coupling independent from its agonistic actions on sarcolemmel Ca 2ϩ channels. These reports found that, aside from its direct positive inotropic effect, BAYK also suppresses SR Ca 2ϩ release and contraction during postrest potentiation, producing a secondary negative inotropic effect. The conclusion from this work was that binding of BAYK to the DHP receptor on the L-type Ca 2ϩ channel had an effect that was somehow translated, through a "functional linkage," to the SR, resulting in a suppression of Ca 2ϩ release (13) . Because this action could arise as a consequence of the maintained leak of Ca 2ϩ from the SR, a subsequent study examined the possibility that BAYK might have a direct action to activate the SR Ca 2ϩ release channel or ryanodine receptor (RyR). However, despite an action of BAYK to increase SR Ca 2ϩ leak, as indicated by increased Ca 2ϩ spark frequency, no direct effect on RyR single-channel activity was observed using a crude vesicular SR preparation (17) .
The purpose of the present study was to further investigate the possibility of a direct agonist effect on the cardiac RyR. We wanted to test for possible actions of DHP agonists on the RyR in the absence of other regulatory proteins because it is known that the type of RyR preparation used (native vesicles vs. purified channels) may influence the RyR response to a ligand (19) . A crude microsome preparation is likely to contain factors in the form of both proteins and other signaling molecules that regulate the RyR. It is possible that, in the process of SR vesicle isolation, these factors may render the vesicular preparation insensitive to activators that might normally be effective under physiological conditions. In addition, it is not yet clear whether these additional regulatory factors operate in SR vesicles, as they would in intact cells, to influence the function and pharmacological sensitivity of RyRs. Thus our sin-gle-channel studies were conducted using the purified RyRs, where it is easier to look for direct ligand/ receptor interactions.
METHODS
Single RyR channel studies. Dog cardiac (n ϭ 5) preparations were obtained from animals anesthetized with pentobarbital sodium (35 mg/kg iv) before removal of the heart. Human hearts were obtained from three normal patients who died as a result of illness unrelated to cardiac disease and whose hearts were donated for research purposes because they were unsuitable for transplant. All animal and human tissue use was subject to review and approval by the Internal Animal Care and Use Committee and the Internal Review Board, respectively.
Crude microsomes were obtained from the left ventricle using differential centrifugation. Purification of the canine cardiac SR Ca 2ϩ release channel was performed using 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate solubilization of heavy SR vesicles with subsequent reconstitution of purified protein into proteoliposomes (1, 9, 10, 20) .
Single-channel recordings were made using the planar lipid bilayer technique with 250 mmol/l KCl and 10 mmol/l HEPES (pH 7.4) on the cis (cytoplasmic) side and trans (luminal) sides of the bilayer. The trans side also contained 1 mmol/l Ca 2ϩ , while cis [Ca 2ϩ ] was measured using a Ca 2ϩ -sensitive electrode as being 5 M. Bilayer composition was 0.4 mg each of phosphatidylserine and phosphatidylethanolamine (Avanti Polar Lipids) suspended in 20 l of ndecane. Pharmacological agents were added directly to either compartment of the bilayer apparatus after control recordings were obtained, and the experimental protocol was repeated after 1 min of stirring (20) .
Single-channel data were recorded (Axopatch 200 and 200A amplifiers, Axon Instruments) using pCLAMP version 6.0 software in data files of 30 s in duration at constant holding potentials (V h ) of Ϯ30, Ϯ40, and Ϯ50 mV in most experiments. Data were filtered with an eight-pole Bessel filter (model 902, Frequency Devices) at 2 kHz, digitized at 5 kHz, and analyzed off-line using half-amplitude threshold algorithms.
In some experiments, [Ca 2ϩ ] was altered by addition of admixtures of EGTA and CaCl 2 according to Calcium software. Concentrations of Ca 2ϩ were varied over the range of 0.1 M to 1 mM in this manner. Channel activity was established with free cis [Ca] ϭ 50 mol/l, and EGTA was then added to reduce [Ca] to 0.1 mol/l. Data were recorded at Ϫ40 mV before [Ca] was increased in a cumulative fashion to 1-1,000 M to obtain [Ca 2ϩ ]-open probability (P o ) curves. Separate experiments were performed in the absence and presence of 10-30 M BAYK.
All chemicals were obtained from Sigma with the exceptions of BAYK (Calbiochem) and (ϩ)-and (Ϫ)-SDZ202-791, which was a gift from Sandoz Pharmaceutical.
Data analysis. Data are presented as means Ϯ SE. Data were compared using paired or unpaired Student's t-tests or a one-way analysis of variance (with secondary comparisons made using a Student-Newman-Keuls test). Differences between sample means were considered significant if P Ͻ 0.05 unless indicated otherwise.
RESULTS

Effects of BAYK on single-channel activity of purified
RyR. Figure 1A shows recordings from a single purified dog cardiac Ca 2ϩ release channel before and during exposure to BAYK (10 mol/l added to the cis side Lifetime analysis of open and closed events indicated that channel P o was increased by BAYK primarily as a result of increased long openings and decreased closings of all durations (Fig. 1B) . Both open and closed events were best described by the sum of two exponentials. In this experiment (V h ϭ Ϫ40 mV), there was a modest increase in short open lifetimes and a large increase in long opening durations with a shift to a lower percentage of short openings. Both durations of closed times were decreased by BAYK, which also induced an increase in the proportion of shorter closings.
Summarized data include the open lifetime events (in ms; n ϭ 9) in control as follows: 1 Thus both open and closed events were significantly altered by BAYK, with a resulting increase in overall P o . Investigation of the relationship between concentration and P o (Fig. 1C ) demonstrated that the BAYK concentration at which 50% of the maximal effect was achieved (EC 50 ) was ϳ3 mol/l. These effects of BAYK occurred in the absence of any change in current magnitude ( Fig. 1D ) and in the absence of any obvious voltage dependence (Fig. 1E) .
Enantiomeric-specific effects of SDZ202-791 on single-channel activity. From the preceding experiments, it was clear that BAYK activated the cardiac Ca 2ϩ release channel as a result of increasing longer openings and promoting shorter closings. We also studied the effects of another DHP agonist, SDZ202-791, whose (ϩ)-and (Ϫ)-enantiomers allowed the separation of agonist and antagonist actions, respectively (5, 7, 22) . As with BAYK, addition of the agonist (ϩ)-SDZ202-791 (100 mol/l) increased P o from 0.29 to 0.90 ( Fig. 2A) . Subsequent addition of the antagonist (Ϫ)-SDZ202-791 (100 mol/l) did not affect the agonist action of the (ϩ)-enantiomer and, in fact, produced a slight increase in P o . In nine experiments, P o was 0.13 Ϯ 4.48 in control and 0.58 Ϯ 0.11 in the presence of 100 mol/l (ϩ)-SDZ202-791 (P Ͻ 0.01). Subsequent addition of the antagonist (Ϫ)-SDZ202-791 caused a small additional increase in P o , probably reflecting a partial agonist effect, increasing P o from 0.41 Ϯ 0.16 to 0.58 Ϯ 0.13 (P Ͻ 0.03, n ϭ 5) after addition of (Ϫ)-SDZ202-791 in the maintained presence of (ϩ)-SDZ202-791. If there were a competitive interaction between the two enantiomers at a common receptor site, we would have expected a reduction in P o under these conditions, which was not observed. Identical results were obtained with BAYK and subsequent exposure to nifedipine (up to 100 mol/l, n ϭ 4; data not shown).
It is possible that the antagonist effect of (Ϫ)-SDZ202-791 is precluded by prior occupancy of an allosteric site during exposure to the (ϩ)-enantiomer. When the order of drug application was reversed (Fig.  2B) , (Ϫ)-SDZ202-791 had no antagonist action on the purified cardiac Ca 2ϩ release channel and again induced a modest activation of the channel. Subsequent addition of (ϩ)-SDZ202-791 then produced the typical agonist effect even after prior exposure to the (Ϫ)-enantiomer. This result was confirmed in two additional experiments. High concentrations of both (Ϫ)-SDZ202-791 and nifedipine (100 mol/l) were responsible for a partial agonist effect, causing an average increase in P o of 0.21 Ϯ 0.04 when added alone (n ϭ 10 or 5 of each type, P Ͻ 0.001). These results demonstrate that the response of the cardiac Ca 2ϩ release channel is selective for specific stereoisomers of the DHP agonists and that there is little response to traditional antagonists. These observations suggest that there is a unique Ca 2ϩ channel agonist effect on the purified cardiac Ca 2ϩ release channel. Additional experiments were performed to identify the location of the modulatory site on the channel protein. After addition of (ϩ)-SDZ202-791 (100 mol/l) to the trans (luminal) side, P o was unchanged (Fig. 2C) . However, subsequent addition to the cis side caused the typical increase in P o from 0.02 to 0.47. Three additional experiments yielded the same results; four experiments with BAYK also yielded an increase in P o only after introduction to the cis side. There was little effect of agonist when applied to the luminal side, and the large increase in P o occurred only when agonist was applied to the cytoplasmic side of the channel. These results indicate that the putative binding site resides on the cytoplasmic face of the channel.
DHP agonists and sensitivity of purified RyR to Ca 2ϩ
concentration. In an attempt to identify the mechanism by which DHP agonists activate the Ca 2ϩ release channel, we studied the relationship between P o and Ca 2ϩ concentration in the absence and presence of DHP agonists (Fig. 3) (Fig.  3, bottom) , there was almost no change in affinity for Ca 2ϩ (EC 50 ϭ 6.8 and 9.6 mol/l in the absence and presence of BAYK, respectively). There was also a modest increase in the Hill coefficient (from 1.45 to 1.98) in the presence of agonist, suggesting an increase in cooperativity for Ca 2ϩ -induced activation. However, the most striking implication of these results is the suggestion that Ca 2ϩ channel agonists bring about Ca 2ϩ release channel activation by suppressing Ca 2ϩ -induced inactivation of the channel.
Effects of DHP agonists on purified human RyR. We also investigated the possibility that the agonist action of DHPs might occur in the human ventricular Ca 2ϩ release channel to determine whether the effect is specific to the dog cardiac RyR and whether this action might have wider implications by its presence in the human heart. Figure 4 shows the effects of BAYK (10 mol/l) on a single purified Ca 2ϩ release channel from a normal human heart. P o increased from 0.11 to 0.47. Subsequent addition of nifedipine (100 mol/l) had no antagonist action on P o (data not shown), and, in fact, there was a slight increase in activity during exposure to the antagonist. Summarized results (n ϭ 3) indicated that P o was 0.23 Ϯ 0.06 in control and 0.74 Ϯ 0.13 in the presence of BAYK. These results demon- strate that the agonist effect occurs in the human ventricular Ca 2ϩ release channel as well as in the dog.
DISCUSSION
DHP agonists and antagonists of L-type Ca 2ϩ channels.
It has been known for many years that DHPs act as antagonists to L-type Ca 2ϩ channels. It was subsequently found that some of these agents have optically active stereoisomers that can act as agonists to I Ca (7, 16, 22) . Thus, in contrast to closely related DHP antagonists, agonists like BAYK increased I Ca magnitude and slowed inactivation, causing increased Ca 2ϩ influx with resultant positive inotropy. Single Ca 2ϩ channel recordings in cardiac cells suggested that the changes in whole cell current were the result of BAYK binding to and stabilizing the highly active state of the channel (4). This type of activity is characterized by prolonged open times with a corresponding reduction in the number and duration of closed events (so-called mode 2 activity) compared with normal activity, which is characterized by brief channel openings during depolarization followed by entry into the inactivated state (mode 1). In contrast, the antagonist action is thought to be a result of the ability of DHPs to bind to and stabilize the inactivated state (mode 0) of the Ca 2ϩ channel, where P o is very low.
Sanguinetti et al. (16) subsequently found that there were complex voltage and concentration dependencies to the effects of BAYK; most notably, I Ca in cardiac Purkinje fibers was increased by BAYK at negative potentials, whereas an antagonistic action was found at depolarized test potentials. They and others (2) demonstrated that this behavior was the result of preferential binding of the two enantiomers of BAYK under the different experimental conditions; the l-or (Ϫ)-enantiomer was a pure agonist, whereas the r-or (ϩ)-enantiomer was an antagonist. Thus a racemic mixture may give conflicting results depending on the concentration and voltage dependencies of the two forms of the drug. Exactly the opposite behavior was observed with another compound, SDZ202-791, whose (ϩ)-enantiomer was an agonist, whereas the (Ϫ)-enantiomer was an antagonist (5, 7, 22) .
We found that the effects of the pure agonists on purified SR Ca 2ϩ release channels were similar to those on I Ca . These agents behaved as if they were stabilizing the channel in mode 2 or the long opening state, just as with I Ca . Thus channel openings were prolonged by reduction in closed times with a simultaneous increase in open times. In striking contrast, the antagonists had no blocking effects, as if there were no equivalent in the Ca 2ϩ release channel to drug-induced stabilization of mode 0 for I Ca . In fact, these agents appeared to cause a modest partial agonist action at the high concentrations used in this study (30-100 mol/l), suggesting that the activating receptor offers at least partial recognition to the opposite (agonist) enantiomer.
Aside from their well-known effects to activate I Ca , our findings have demonstrated a similar action on the cardiac RyR. Specifically, our observations indicate that the action of DHP agonists on the cardiac RyR is selective for activation of a recognition site on the channel. DHP antagonists did not directly reduce activity nor did they antagonize the increase in channel activity resulting from prior exposure to agonists. These results suggest that the antagonists do not occupy a binding site on the RyR and thus do not affect channel activity directly or displace previously bound agonist. Even more important is the fact that there is a clear stereospecificity to the agonist action, which supports the notion that channel activation is a result of a specific interaction with the RyR and not of nonspecific drug effects.
One of the most intriguing results reported here is that the effect of DHP agonists may involve a suppression of Ca 2ϩ -induced inactivation. This property of the RyR has been well documented and is thought to reflect binding of Ca 2ϩ at high concentrations to a low-affinity site inducing channel closure (3, 14, 17) . We found that high-affinity Ca 2ϩ -induced activation of channel activity was nearly unaffected by agonists, whereas inactivation was largely suppressed. This unusual observation is among the first to suggest the possibility that pharmacological activation of the cardiac RyR by certain agents might occur through selective inhibition of Ca 2ϩ -induced inactivation. Calcium channel agonists and cardiac excitationcontraction coupling. The possibility that the effect of BAYK on excitation-contraction coupling might involve an action on the SR as well as on the L-type Ca 2ϩ channel came from work by Bers and co-workers (6, 12, 13, 17) . BAYK produced an increase of Ca 2ϩ influx through I Ca but also accelerated the decline of the SR Ca 2ϩ content during rest, thus converting the typical potentiation of contraction after rest to a decay in both the dog and ferret ventricle.
One of the previous studies (13) also found that BAYK enhanced ryanodine binding, suggesting an increase in RyR channel P o . These investigators concluded that the effect of BAYK occurs as a result of a modification of the L-type Ca 2ϩ channel, which is then transmitted via a functional linkage to the SR, causing alterations in SR Ca 2ϩ release. More recently, BAYK was found to increase the frequency of local changes in intracellular [Ca 2ϩ ] (Ca 2ϩ sparks) without altering their spatial or temporal characteristics (17) . This action was strikingly similar to the effects on Ca 2ϩ sparks of low concentrations of ryanodine, which locks the RyR channel in a permanently open state. Virtually all of these results support the idea that BAYK might induce a reduction in SR Ca 2ϩ content, possibly as the result of a ryanodine-like action to promote long-lasting activation of the RyR channels. When this possibility was directly studied in crude SR vesicular Ca 2ϩ release channels isolated from the ferret heart (17), BAYK was found to have no effect on singlechannel activity. The authors concluded that BAYK activates SR Ca 2ϩ release at rest but that the effect of BAYK is indirect via an action on the DHP receptor on L-type Ca 2ϩ channels that is transmitted by an unknown mechanism to the SR Ca 2ϩ release channel. In contrast with the results obtained by Satoh et al. (17) , our observations suggest that this effect on SR Ca 2ϩ release may be the result of a direct action on the Ca 2ϩ release channel itself and may occur independently of any interactions with sarcolemmal proteins, such as the L-type Ca 2ϩ channel. It is well known that DHPs are very lipophillic, often with a partition coefficient (oil:water) of ϳ3 (8, 21) , so it is highly likely that these agents can easily cross the sarcolemma. The intracellular accumulation of DHPs has in fact been directly demonstrated in ventricular tissue (15) . Once in the cytoplasm, they can then gain access to the recognition site on the SR Ca 2ϩ release channel with the resulting functional response of the channel depending on the regulatory factors and mechanisms involved. A direct action of DHP agonists on purified RyRs is consistent with the observations of Satoh et al. (17) , who found significant alterations in Ca 2ϩ spark frequency, as would be expected for an agent that increases single RyR channel activity. In addition, a direct effect offers a reasonably straightforward explanation for their findings as well as for the other reported suppressant effects of BAYK on excitation-contraction coupling (6, 12, 13, 17) .
It is possible that our single-channel data differ from those of Satoh et al. (17) because of differences in experimental conditions. For example, the different response to BAYK of our purified RyRs could arise as a consequence of something as simple as a difference in charge carrier (K ϩ in the current study compared with Cs ϩ in Ref. 17) . However, there have been few reported differences in pharmacological or physiological sensitivities using different monovalent cationic species (3, 14) . A more likely explanation may lie in the possibility that the purification process could alter the pharmacological sensitivity of the RyR. The difference in response to DHP agonists suggests that there are factors associated with the crude channel, possibly but not necessarily proteinaceous in nature, that either preclude access of an agonist to its receptor or regulate the response to the activated receptor in some fashion. We do not yet know which form of the channel more accurately reflects channel behavior under physiological conditions, so it is difficult at this point to determine the role of these regulatory factors in influencing the pharmacological responses of the channel in vivo.
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